Profound Medical to Present Business Update at Conference

Profound Medical ( (TSE:PRN) ) just unveiled an update.

On April 14, 2026, Profound Medical Corp. announced that its management would present a business update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026, at the Metro Toronto Convention Centre, with the session also available via live webcast. The event provides the company with a platform to showcase progress and strategy to the healthcare investment community, potentially enhancing investor visibility and reinforcing its positioning in the MRI-guided therapy segment.

By participating in a high-profile healthcare investor conference, Profound is underscoring its commercial-stage status and the global footprint of its TULSA-PRO and Sonalleve platforms. This outreach to investors may influence perceptions of the company’s growth trajectory, support access to capital over time, and highlight its role in advancing non-invasive, MRI-guided treatment options in the medical device industry.

The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$12.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.

Spark’s Take on PRN Stock

According to Spark, TipRanks’ AI Analyst, PRN is a Neutral.

The score is held down primarily by weak financial performance (large losses and significant cash burn) and bearish technicals (downtrend across key moving averages with negative momentum). The earnings call adds support via credible growth/profitability targets, reimbursement and pipeline tailwinds, while valuation remains constrained by ongoing losses and no stated dividend.

To see Spark’s full report on PRN stock, click here.

More about Profound Medical

Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Its flagship TULSA-PRO platform enables real-time, MRI-guided prostate therapy, while its Sonalleve system offers non-surgical treatment options for bone metastases, select tumors, and gynecologic conditions across major global markets.

Both TULSA-PRO and Sonalleve are cleared or approved in key jurisdictions, including the United States, Europe, Canada, and several markets in the Middle East and Asia-Pacific. By focusing on precise, personalized, and incision-free treatments that can reduce common side effects and recovery times, Profound aims to advance interventional MRI procedures and broaden access to next-generation therapeutic options worldwide.

Average Trading Volume: 19,159

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$298M

For an in-depth examination of PRN stock, go to TipRanks’ Overview page.